Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of GoodRx Holdings Inc (NASDAQ: GDRX) was $4.48 for the day, down -1.10% from the previous closing price of $4.53. In other words, the price has decreased by -$1.10 from its previous closing price. On the day, 1.39 million shares were traded.
Ratios:
Our analysis of GDRX’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.32 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.69. For the most recent quarter (mrq), Quick Ratio is recorded 5.23 and its Current Ratio is at 5.23. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.81.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on December 04, 2024, initiated with a Neutral rating and assigned the stock a target price of $5.
On August 09, 2024, Raymond James Upgraded its rating to Strong Buy which previously was Outperform but kept the price unchanged to $10.
RBC Capital Mkts Upgraded its Sector Perform to Outperform on May 23, 2024, whereas the target price for the stock was revised from $8 to $10.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 06 ’25 when Spectrum Equity VII, L.P. sold 10,677 shares for $4.09 per share. The transaction valued at 43,706 led to the insider holds 0 shares of the business.
Spectrum VII Investment Manage bought 6,828 shares of GDRX for $27,312 on Jun 06 ’25. On Jun 06 ’25, another insider, Spectrum VII Co-Investment Fun, who serves as the Affiliate of the company, bought 3,849 shares for $4.00 each.
Valuation Measures:
As of this moment, GoodRx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 60.30, and their Forward P/E ratio for the next fiscal year is 9.78. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.11. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.01 while its Price-to-Book (P/B) ratio in mrq is 2.47.
Stock Price History:
Over the past 52 weeks, GDRX has reached a high of $9.26, while it has fallen to a 52-week low of $3.67. The 50-Day Moving Average of the stock is 5.11%, while the 200-Day Moving Average is calculated to be -13.80%.
Shares Statistics:
A total of 103.94M shares are outstanding, with a floating share count of 83.18M. Insiders hold about 76.71% of the company’s shares, while institutions hold 16.03% stake in the company.
Earnings Estimates
GoodRx Holdings Inc (GDRX) is presently subject to a detailed evaluation by 12.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.1, with high estimates of $0.11 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.43 and $0.35 for the fiscal current year, implying an average EPS of $0.39. EPS for the following year is $0.46, with 13.0 analysts recommending between $0.5 and $0.41.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 14 analysts. It ranges from a high estimate of $207.5M to a low estimate of $204.7M. As of the current estimate, GoodRx Holdings Inc’s year-ago sales were $200.61MFor the next quarter, 14 analysts are estimating revenue of $205.23M. There is a high estimate of $210.31M for the next quarter, whereas the lowest estimate is $201M.
A total of 16 analysts have provided revenue estimates for GDRX’s current fiscal year. The highest revenue estimate was $830.97M, while the lowest revenue estimate was $814.1M, resulting in an average revenue estimate of $819.9M. In the same quarter a year ago, actual revenue was $792.32MBased on 16 analysts’ estimates, the company’s revenue will be $863.89M in the next fiscal year. The high estimate is $896.33M and the low estimate is $834.3M.
